Navigation Links
Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
Date:1/5/2012

DEERFIELD, Ill., Jan. 5, 2012 /PRNewswire/ -- Baxter International Inc. today announced the dosing of the first patients in a Phase I clinical trial of its lead investigational candidate, BAX 855, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein.  BAX 855 is based on Baxter's ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] full-length rFVIII molecule and plasma/albumin-free (PAF) manufacturing process.

The Phase I trial is a prospective, open-label study that will assess the safety, tolerability and pharmacokinetics of BAX 855 in previously-treated patients aged 12 years or older with severe hemophilia A.  When used for prophylaxis, Baxter's ADVATE requires patients to infuse every two to three days to reduce the occurrence of bleeding episodes.  This Phase I trial is the first step in assessing whether BAX 855 can be infused less frequently. 

"This trial is designed to provide new insights about our investigational longer-acting FVIII molecule, BAX 855, with the ultimate goal of improving care for patients living with hemophilia A," said Prof. Hartmut J. Ehrlich, M.D., vice president of global research and development in Baxter's BioScience business. "The Phase I results will serve as the foundation for advancing this important program through clinical development and determining whether BAX 855 can offer a treatment regimen requiring fewer infusions than ADVATE."

BAX 855 employs Baxter's proprietary full-length plasma/albumin-free recombinant protein platform that does not contain any human or animal-derived additives. BAX 855 leverages Nektar Therapeutics' (NASDAQ: NKTR) proprietary PEGylation technology, which is designed to extend the duration of activity of proteins and larger molecules.  Baxter and Nektar have a collaboration to develop PEGylated products designed
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Hikma Expands its Global Injectables Business Through the Acquisition of Baxter Healthcare Corporations Multi-Source Injectables Business
2. Variation Biotechnologies Names Jeff Baxter CEO
3. Baxter International First Quarter 2009 Financial Results Conference Call
4. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
5. Halozyme Receives $5.5 Million Payment From Baxter
6. Frost & Sullivan Awards Baxters BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award
7. AmeriCares Presents Power of Partnership Award to Baxter
8. Baxter International Third Quarter 2008 Financial Results Conference Call
9. Baxter Named to Dow Jones Sustainability Index for Tenth Consecutive Year
10. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
11. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
(Date:1/15/2014)... 15, 2014 The Microcompetition with Foreign DNA ... One of these latent viruses is the Epstein Barr Virus ... Rheumatoid arthritis (RA) is a chronic inflammatory disease that destroys ... found that RA patients have high concentrations of EBV DNA ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of Notched ... tinnitus. Patients listen to sound therapy that is tailor-made ... weeks to months, their tinnitus volume decreases. , AudioNotch has ... and Notched White Noise. Now, AudioNotch is pleased to announce ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... team of physicists at UC Santa Barbara has seen the ... high- and low-frequency laser beams at a semiconductor, the researchers ... then smashed back into the cores they left behind. This ... in the current issue of the science journal Nature ...
... March 30, 2012  Human Pheromone Sciences, Inc. (EROX) ("HPS" or ... Company filed a Form 15 with the SEC in order ... under the Securities Exchange Act of 1934.  Upon this voluntary ... and current reports with the SEC, including Forms 10-K, 10-Q ...
... 28, 2012   Luminex Corporation  (NASDAQ: ... vice president of Biodefense will present at ... taking place March 27-29, 2012 in Denver, Colorado. The meeting ... Joint Program Executive Office for Chemical and ...
Cached Biology Technology:UCSB Physicists mix 2 lasers to create light at many frequencies 2UCSB Physicists mix 2 lasers to create light at many frequencies 3Human Pheromone Sciences Voluntarily Files With SEC for Termination of Registration 2Human Pheromone Sciences Voluntarily Files With SEC for Termination of Registration 3Human Pheromone Sciences Voluntarily Files With SEC for Termination of Registration 4Human Pheromone Sciences Voluntarily Files With SEC for Termination of Registration 5Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference 2Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference 3Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference 4
(Date:4/17/2014)... April 17 In the most densely forested and ... reflect two centuries of human needs, values and practices. ... clearing forests for agriculture and development, have set the ... U.S. Forest Service study reports. , The report ... and management needs in the Northern United States ...
(Date:4/17/2014)... peppers. Information about archaeological remains of ancient chili peppers ... of words for chili peppers in ancient dialects helped ... the value of multi-proxy data analysis. Their results are ... presented in a special feature issue of the ... plant and animal domestication edited by Dolores Piperno, staff ...
(Date:4/17/2014)... new modeling study suggests that fish consumption advisories ... exposure to long-lived contaminants like persistent organic pollutants ... team of researchers including University of Toronto Scarborough ... looks at how different levels of environmental contamination, ... of chemicals in the body influenced exposure in ...
Breaking Biology News(10 mins):Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3Chickens to chili peppers 2Chickens to chili peppers 3Fish consumption advisories fail to cover all types of contaminants 2
... is not a word typically associated with trees; they can take ... week of Feb. 1 in the Proceedings of the National ... Eastern United States are growing faster than they have in the ... an ecosystem is responding to ,climate change. For more than ...
... Calif. Biologists have known for long that ecology, ... significant role in forming new species and in modifying ... shapes evolution. The environment defines a template and the ... fit that template. Some specialized theory, ...
... Feb. 1, 2010) -- Mapping DNase I hypersensitive ... genetic regulatory elements such as promoters, enhancers, silencers, insulators, ... to provide access for transcription factors, are selectively digested ... blots to then identify these hypersensitive sites. In ...
Cached Biology News:Ecologists discover forests are growing faster 2Ecologists discover forests are growing faster 3Evolution impacts environment, challenging traditionally held view, UC Riverside study finds 2Evolution impacts environment, challenging traditionally held view, UC Riverside study finds 3High-throughput analysis of gene regulation, DNA synthesis in Cold Spring Harbor Protocols 2
Automated -80° C sample library for microplates and cryotube racks in SBS format; for integration into automated processes....
... PROTECT FROM MOISTURE. AVOID FREEZE/THAW CYCLES. This ... in vitro by DNA affinity-mediated ... anti-histone-facilitated detection. In this assay, mono- and ... proteins. Anti-Histone 3 (H3) biotin-labeled antibody then ...
OptiBuffer is a fully optimised medium, designed for,the electroporation of eukaryotic cells. OptiBuffer,improves both transfection efficiencies and survival,rates over PBS or other standard culture...
OmniSlide Heated Wash Module. 2 independent chambers with precise temperature control from ambient of 5C to 70C. Each chamber holds 1 slide rack (20 slides). Includes 2 x Wash Sleeves, 1 x Slide R...
Biology Products: